CDK3: A Potential Drug Target and Biomarker (G1018)

Target Name: CDK3

NCBI ID: G1018

CDK3

CDK3: A Potential Drug Target and Biomarker

CDK3 (Chromatin-Remodeling Complex subunit 3) is a protein that plays a crucial role in the regulation of DNA replication in the cell. It is a key component of the chromatin complex, which is responsible for the production of new DNA copies during the cell cycle. CDK3 functions by interacting with the template DNA and the histone proteins, which are essential for the initiation and progression of DNA replication.

CDK3 has been identified as a potential drug target in the field of cancer. Its involvement in the regulation of DNA replication makes it an attractive target for therapies that aim to inhibit cell proliferation. Additionally, CDK3 has been shown to be overexpressed in various types of cancer, which suggests that it may be a useful biomarker for the diagnosis and monitoring of these diseases.

CDK3 functions as a protein that plays a critical role in the regulation of DNA replication. It is a key component of the chromatin complex, which is responsible for the production of new DNA copies during the cell cycle. CDK3 functions by interacting with the template DNA and the histone proteins, which are essential for the initiation and progression of DNA replication.

One of the key functions of CDK3 is its role in the regulation of the timing of DNA replication. CDK3 is involved in the recruitment of the histone proteins to the centromere region of the chromosome, which is critical for the proper separation of the replicated chromosomes during the cell cycle. Additionally, CDK3 is involved in the regulation of the exit of the chromatin fiber, which is a complex structure that makes up the chromosome.

In addition to its role in regulating DNA replication, CDK3 is also involved in the regulation of gene expression. It has been shown to play a role in the regulation of various gene expression pathways, including cell growth, differentiation, and apoptosis. This suggests that CDK3 may be a useful target for drugs that aim to modulate gene expression in cancer cells.

CDK3 has also been shown to be involved in the regulation of cellular processes that are important for the development and progression of cancer. For example, studies have shown that CDK3 is involved in the regulation of cell adhesion, which is critical for the maintenance of cancer cell stemness. Additionally, CDK3 has been shown to play a role in the regulation of cell migration, which is critical for the development of cancer stem cells that can give rise to new tumors.

In conclusion, CDK3 is a protein that has important roles in the regulation of DNA replication and gene expression in the cell. Its involvement in the regulation of DNA replication makes it an attractive target for drugs that aim to inhibit cell proliferation. Additionally, its involvement in the regulation of various cellular processes that are important for the development and progression of cancer makes it a potential biomarker for the diagnosis and monitoring of these diseases. Further research is needed to fully understand the role of CDK3 in cancer biology and to develop effective therapies that target this protein.

Protein Name: Cyclin Dependent Kinase 3

Functions: Serine/threonine-protein kinase that plays a critical role in the control of the eukaryotic cell cycle; involved in G0-G1 and G1-S cell cycle transitions. Interacts with CCNC/cyclin-C during interphase. Phosphorylates histone H1, ATF1, RB1 and CABLES1. ATF1 phosphorylation triggers ATF1 transactivation and transcriptional activities, and promotes cell proliferation and transformation. CDK3/cyclin-C mediated RB1 phosphorylation is required for G0-G1 transition. Promotes G1-S transition probably by contributing to the activation of E2F1, E2F2 and E2F3 in a RB1-independent manner

The "CDK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets